Tirzepatide (Mounjaro / Zepbound / 穆桂諾) Tirzepatide × 脂肪肝 MASLD/MASH
結論：證據支持但有警示
Tirzepatide 用於 MASLD/MASH 為 OFF-LABEL 使用（FDA/EMA/TFDA 皆未核准此適應症，截至 2026-06）。
C 🟠 C 薄弱證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
Tirzepatide 用於 MASLD/MASH 為 OFF-LABEL 使用（FDA/EMA/TFDA 皆未核准此適應症，截至 2026-06）。
最重要的單一證據為 SYNERGY-NASH Phase 2b RCT（NEJM 2024, n=190, 52 週），三組劑量 5/10/15 mg 之 MASH 緩解率（無纖維化惡化）為 51.8%/62.8%/73.3%，顯著優於安慰劑 13.2%（PMID 38856224），且 EASL-EASD-EASO 2024 指引將其列為合併 T2D/肥胖之 MASLD 共病管理選項，Cleveland Clinic 與 Harvard Health 亦正面評價。
考量證據強度為單一 Phase 2b RCT（樣本中等、非侵入性纖維化生物標記未達顯著、Phase 3 SYNERGY-NASH-2 結果未發布）、加上 resmetirom 為唯一 FDA 核准 MASH 藥物之競爭定位，獨立評為 B（promising but not yet first-line/on-label）。
若僅看 obesity/T2D pivotal trials 則為 A，但本評分鎖定 MASLD/MASH 適應症。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.65
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 附警語發布
信心度
82%
證據方向一致性高
證據層級
E7
單篇小型隨機對照試驗
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.653
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — B 級條件未達 (需 E1-E6；實際 E7)
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH)
— 詳細結論請見 PubMed 原文
前往 PubMed
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for MASH
— 詳細結論請見 PubMed 原文
前往 PubMed
Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives
— 詳細結論請見 PubMed 原文
前往 PubMed
Relationship Between Metabolic and Histological Responses in People With MASH With and Without T2D: SYNERGY-NASH Participant-Level Exploratory Analysis
— 詳細結論請見 PubMed 原文
前往 PubMed
Tirzepatide in Metabolically Dysfunctional-Associated Steatohepatitis (MASH): A Bibliometric and Evidence-Based Review
— 詳細結論請見 PubMed 原文
前往 PubMed
L4a US FDA
支持
MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. WARNING: RISK OF THYROID C-CELL TUMORS — Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell … 來源↗
L4b EU EFSA
支持
Mounjaro received a marketing authorisation valid throughout the EU on 15 September 2022. The active substance in Mounjaro, tirzepatide, acts in the same way as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Mounjaro is a prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct… 來源↗
L4c UK NHS
支持
Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index (BMI) of at least 35 kg/m2 and at least 1 weight-related comorbidity. If less than 5% of the initial weight has been lost after 6 months on the highest tolerated dose, decide whether to continue tre… 來源↗
L4d TW TFDA / 衛福部
支持
猛健樂注射劑15毫克/0.5毫升 (MOUNJARO Injection 15mg/0.5mL)；許可證字號：衛部藥輸字第028468號；限由醫師使用；適應症：(1) 作為飲食及運動療法之外的輔助治療，用於改善第二型糖尿病成人病人之血糖控制；(2) 作為飲食及運動療法之外的輔助治療，用於體重控制（肥胖或過重）；申請商：台灣禮來股份有限公司；發證日期：112-07-19 來源↗
L4e WHO
支持
Tirzepatide (GLP-1/GIP dual receptor agonist) used as glucose lowering therapy for adults with type 2 diabetes mellitus with established cardiovascular disease or chronic kidney disease and obesity. High prices of medicines like semaglutide and tirzepatide are limiting access to these medicines. 來源↗
L5a NIH Office of Dietary Supplements
支持
Tirzepatide functions as a dual agonist with greater affinity to GIP receptors than to GLP-1 receptors. FDA approvals: Type 2 Diabetes (Mounjaro) - May 2022 as adjunct to diet and exercise for glycemic control; Obesity (Zepbound) - November 2023 for chronic weight management in adults with obesity or overweight plus comorbidities; Obstructive Sleep Apnea (Zepbound) - December 2024 for moderate-… 來源↗
L5b Mayo Clinic
中性
Tirzepatide injection is used to treat type 2 diabetes, used together with diet and exercise to help control blood sugar. Tirzepatide injection is also used to help lose weight and keep the weight off in patients with obesity caused by certain conditions. It is also used to treat moderate to severe obstructive sleep apnea (OSA) in patients with obesity. 來源↗
L5c Cleveland Clinic
支持
These drugs reduce inflammation and fat in your liver. Examples are liraglutide (Victoza®, Saxenda®) semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®). 來源↗
L5d Harvard Health
支持
Obesity drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound) appear promising for reversing MASLD. 來源↗
L5e Specialty Society (condition-mapped)
謹慎
optimal management of comorbidities—including use of incretin-based therapies (e.g. semaglutide, tirzepatide) for type 2 diabetes or obesity 來源↗
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽
PTT MuscleBeach 板心得文與推文均回報施打猛健樂（Tirzepatide）後脂肪肝明顯改善：原PO體重 83→77 kg、GPT 由 60+ 降至 40+；推文使用者更回報一個月脂肪肝消失、肝指數由 60+ 降至 20+。在台灣，Tirzepatide（Zepbound/Mounjaro）對 MASLD/MASH 屬於 OFF-LABEL（仿單核准適應症為第 2 型糖尿病與體重管理，尚未取得 MASH 適應症），社群普遍將改善歸因於體重下降帶來的肝臟脂肪減少。
💬社群實感
多數正面
破解迷思 社群最常見的 5 個誤解
✓
事實誤以為猛健樂在台灣已核准用於治療脂肪肝（實際上為 OFF-LABEL，仿單適應症為糖尿病與體重管理）
✓
事實誤以為肝指數下降是藥物直接護肝，實際上主要是體重下降與內臟脂肪減少的間接效果
✓
事實誤以為打了就一勞永逸，忽略停針後復胖與脂肪肝可能回升的風險
✓
事實誤以為自費購買網路或中國代購來源安全（仿冒品與儲存不當問題嚴重）
✓
事實誤以為高劑量(15 mg)效果一定更好、忽略每 4 週調量原則與腸胃副作用
🩹 社群通報的副作用
- 噁心、嘔吐（最常見，調量初期最明顯）
- 腹瀉與便祕交替
- 食慾不振、進食量驟減
- 臉部凹陷（俗稱『猛健樂臉』）與掉髮
- 停針後復胖與肝指數回升
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- 猛健樂 Mounjaro（禮來 Eli Lilly，台灣 TFDA 核准）
- 穆峰達（Mounjaro 中國名稱，PTT China_Travel 板心得提及）
- Zepbound（美國減重適應症品名，社群常與 Mounjaro 並提）
- 勤美學診所、博田國際健康管理中心、蒼嵐健康美學診所（台灣常見處方診所）
- 小宙醫學診所、金芝妍醫美診所（台灣常見處方診所）
- 週纖達 Wegovy（Semaglutide，常被拿來與猛健樂比較）
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 減重 7-10%
- 地中海飲食
- Resmetirom (Rezdiffra)
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-masld-INT-tirzepatide-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "Tirzepatide (Mounjaro / Zepbound / 穆桂諾)能改善脂肪肝 MASLD/MASH",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}